Paper: Replacing the Anthracycline By Gemtuzumab Ozogamicin in Older Patients with De Novo Standard-Risk Acute Myeloid Leukemia Treated Intensively – Results of the Randomized ALFA1401-Mylofrance 4 Study

RTC of GO+Cytarabine V. 7+3 in older patients (60-80) with CD33+ de novo AML. Unfortunately replacing the anthracycline with an ADC had inferior outcomes and increased toxicity.

Read the full article here

Related Articles